Arrowhead Pharmaceuticals, Inc. (ARWR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 35.15 |
| Open | 36.01 |
| Bid | 31.68 x 1200 |
| Ask | 36.21 x 1300 |
| Day's Range | 33.90 - 36.64 |
| 52 Week Range | 27.87 - 93.66 |
| Volume | |
| Avg. Volume | 800,931 |
| Market Cap | 3.785B |
| Beta (5Y Monthly) | 1.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.36 |
| Earnings Date | May 02, 2022 - May 06, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 80.45 |
- Zacks Small Cap Research
ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway…
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Cardiometabolic Programs Progressing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has two late-stage cardiometabolic programs, ARO-APOC3 and ARO-ANG3. ARO-APOC3 is targeted to apolipoprotein C-III (APOC3), a component of very low-density lipoprotein (VLDL) and an inhibitor of lipoprotein lipase. This program is
- Business Wire
Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
PASADENA, Calif., May 10, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal second quarter ended March 31, 2022. The company is hosting a conference call today, May 10, 2022, at 4:30 p.m. ET to discuss the results.
- Business Wire
Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives
PASADENA, Calif., May 09, 2022--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today held a groundbreaking ceremony in Verona, WI, on the site which will house a new approximately 160,000 square foot drug manufacturing facility and an approximately 125,000 square foot laboratory and office facility to support process development and analytical activities. The Company also announced that it received awards for up to $16 million in tax increment financing from the city of Verona, and up to $2.5 mi
